EWP
NVCR icon

Elevation Wealth Partners’s NovoCure NVCR Stock Holding History

Elevation Wealth Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$27.6K Buy
1,731
+1,147
+196% +$19.1K 0.01% 571
2026
Q2 		$8.85K Buy
584
+473
+426% +$7.16K ﹤0.01% 845
2026
Q1 		$1.21K Sell
111
-106
-49% -$1.32K ﹤0.01% 977
2025
Q4 		$2.81K Buy
217
+55
+34% +$706 ﹤0.01% 741
2025
Q3 		$2.09K Buy
+162
New +$2.16K ﹤0.01% 638

Other funds holding NVCR

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Elevation Wealth Partners's NVCR Position: Q3 2026 in Review

Elevation Wealth Partners increased its NovoCure (NVCR) stake by 196% in Q3 2026, buying an estimated $19.1K and bringing the position to 1,731 shares worth $27.6K. The position accounts for 0.01% of the portfolio, ranked #571.

Elevation Wealth Partners first reported a position in NVCR in Q3 2025 and has held it in 5 quarters since. 15 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • Elevation Wealth Partners held 1,731 shares of NovoCure worth $27.6K as of Q3 2026.
  • Elevation Wealth Partners bought 1,147 NovoCure shares in Q3 2026, an estimated $19.1K.
  • NovoCure made up 0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #571 holding.
  • Elevation Wealth Partners first reported a position in NovoCure in Q3 2025 and has held it in 5 quarters since.
  • 15 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.